Contract Assay Development
& Bioconjugation Services

Sustainability in lateral flow testing is broader than material substitution. This article explores how material design, reagent strategy, manufacturing yield, performance testing, supply chain choices and at-source testing can reduce waste across the full lateral flow test lifecycle.

Fleet Bioprocessing is attending Med-Tech Expo 2026 at the NEC Birmingham on Wednesday 3rd June. We look forward to meeting researchers and industry partners working in diagnostics, assay technologies and healthcare innovation.

This article compares sandwich vs competitive assays in ELISA and lateral flow, focusing on format selection, reagent strategy and assay development considerations.

Performance verification is the stage at which a lateral flow assay moves from development understanding to formal analytical evidence. This article explains how intended use and design inputs shape verification strategy, how CLSI-guided studies are structured, and why robust documentation is critical for transfer, submission, and product readiness.

Preparing a lateral flow assay for transfer means moving from a feasible prototype to a process that can be controlled, reproduced, and sustained in manufacture. This article explores what transfer readiness really means, how robustness studies, pilot batches, documentation, training, and validation fit together, and how to establish a process that can support routine production.

This article explains how lateral flow assay scale-up and manufacture depend on robust design, material selection, process tolerances, reel-to-reel control, drying and assembly consistency.

This guide to lateral flow assay development explains how to improve assay sensitivity and reproducibility through antibody screening, membrane selection, conjugate optimisation, strip design and process control.

In this article, we explore how sample type and matrix effects influence lateral flow assay (LFA) performance, going beyond initial antibody selection and detector optimisation. Real-world samples such as whole blood, saliva, urine, swab extracts, and environmental matrices introduce variability, chemical interference, and flow challenges that can significantly impact sensitivity, specificity, and reproducibility.